(Circulation. 2000;102:2058.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Epidemiological and Genetic Associations of Activated Factor XII Concentration With Factor VII Activity, Fibrinopeptide A Concentration, and Risk of Coronary Heart Disease in Men
From the Department of Medicine, University College London Medical School, Rayne Institute, London, UK (F.Z., F.D., S.E.H.); MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, UK (S.R.B., G.J.M.); Biometrics Department, Pfizer Central Research, Sandwich, Kent, UK (S.R.B.); Nuffield Department of Clinical Biochemistry, University of Oxford, Radcliffe Infirmary, Oxford, UK (M.P.E.); and Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City (J.H.M.).
Correspondence to G.J. Miller, MD, FRCP, MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ. E-mail g.miller{at}mds.qmw.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—The relations of plasma activated factor XII (FXIIa) concentration and a common polymorphism (C46T) of the factor XII gene with hemostatic status and risk of coronary heart disease (CHD) were examined by prospective surveillance.
Methods and Results—Genotyping for the C46T variant was performed in 2624 men 50 to 61 years of age who were free of CHD at baseline. The genotype distribution was as follows: CC, 56.7%; CT; 36.9%; and TT, 6.6%. Plasma FXIIa was measured by ELISA on 1745 samples collected 1 year after baseline; median levels were (ng/mL) CC, 2.0; CT, 1.4; and TT, 0.8 (P<0.0001). Respective values for plasma fibrinopeptide A (FPA, nmol/L) were 1.52, 1.35, and 1.15 (P<0.0001); for factor VII coagulant activity (FVIIc, % standard), 114.5, 116.2, and 109.3 (P=0.02). Group differences in FVIIc were unchanged by adjustment for body mass index and serum triglycerides. Whereas CHD incidence did not differ significantly by genotype, rates (per 1000 person-years) by thirds of FXIIa distribution were for <1.5 ng/mL, 7.2; for 1.5 to 2.0 ng/mL, 7.2; and for >2.0 ng/mL, 13.6. Respective hazard ratios with the low third as reference group were 1.01 and 1.96 (P=0.007), which were essentially unchanged after allowance for genotype, blood lipids, blood pressure, body mass index, FVIIc, and FPA.
Conclusions—The C46T polymorphism is a determinant of FXIIa, FPA, and possibly FVIIc, suggesting that FXII influences the activity state of the coagulation pathway and FPA cleavage from fibrinogen in vivo. Plasma FXIIa is increased in middle-aged men at high risk of CHD.
Key Words: coronary disease • genes • coagulation • epidemiology
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The contact system consists of the plasma proteins factor XII (FXII), prekallikrein, factor XI, and high-molecular-weight kininogen.1 The step initiating activity is the conversion of FXII to its derivative enzyme FXIIa, achieved in vitro (but not yet demonstrated unequivocally in vivo) by contact with substances having a negatively charged surface.2 3 Human endothelial cells possess receptors for FXII4 and high-molecular-weight kininogen.5 Production of FXIIa creates the potential for dissemination of reactions along several pathways concerned with tissue defense and repair,6 7 8 9 10 11 including the conversion of plasminogen to the fibrinolytic enzyme plasmin12 and activation of factor IX (FIX)13 and factor VII (FVII)14 in the coagulation system. Some of these actions have been demonstrated only in vitro, however, and their relevance for health is poorly understood.
When FXII coagulant activity (FXIIc) and FXII antigen (FXIIag) were measured in survivors of an acute myocardial infarction (MI) and healthy subjects, the former had significantly raised levels in one study15 but not in another.16 A clinical study reported FXIIa to be significantly higher in survivors of MI than in healthy control subjects.17 An earlier analysis of the present study showed that FXIIa was positively and independently associated with the major conventional risk factors for coronary heart disease (CHD).18 Here, the relations of plasma FXIIa concentration and a common (C46T) polymorphism of the FXII gene19 with risk of CHD have been explored by prospective surveillance.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Subjects and Procedures
Details of the survey, the Second Northwick Heart Study, have been reported previously.20 Briefly, 4600 men 50 to 61 years of age belonging to 9 general medical practices were screened for eligibility. Those with evidence of MI on the ECG, a history of unstable angina, MI, regular medication with aspirin or anticoagulants, cerebrovascular disease, life-threatening malignancy, or other infrequently specified characteristics20 were excluded, leaving 2951 for study. Recruitment began before the assay for FXIIa became available, so those measurements were made on samples stored at the first annual reexamination.
Participants attended for examination in a nonfasting state, having been requested not to smoke or undertake vigorous exercise from the midnight before. A 23-mL blood sample was taken and processed as described elsewhere.20 Silicon-coated tubes were used to collect 4.5 mL of blood into 0.5 mL of 0.106 mol/L trisodium citrate anticoagulant and 13.5 mL into 1.5 mL of a commercial anticoagulant containing trasylol, EDTA, and a chloromethylketone thrombin inhibitor (Byk-Sangtec). Plasma levels of prothrombin fragment F1+2 in blood collected in this anticoagulant are in excellent agreement with those in samples taken into an anticoagulant mixture of acid citrate dextrose, EDTA, adenosine, and heparin.21 A 5-mL blood sample was taken for serum.
Assays were performed on citrated plasma except when indicated. FVII coagulant activity (FVIIc)22 and activated FVII (FVIIa)23 were measured by 1-stage bioassay. FVII antigen (FVIIag) concentration was measured by ELISA (Novo Nordisk, Bagsvaerd). Fibrinogen concentration was measured by a thrombin-clotting method24 with the use of a standard plasma (Immuno) calibrated against a World Health Organization (WHO) international standard (89/644). Prothrombin fragment F1+2 and fibrinopeptide A (FPA) were measured in plasma collected into the commercial anticoagulant. Plasma F1+2 was measured by double-antibody radioimmunoassay25 and FPA was measured by commercial radioimmunoassay (Byk-Sangtec) as indexes of prothrombin and fibrinogen turnover, respectively. Plasma apparent FXIIa was measured by an ELISA with a monoclonal antibody specific for FXIIa26 (Axis-Shield). Serum cholesterol and triglyceride concentrations were measured by automated enzyme procedures (Sigma and Wako Chemicals [Alpha Laboratories], respectively).
For apparent FXIIa, the within-person coefficient of variation of measurements made during the study was 10.5%, while the within-run coefficient of variation of assays of split samples was 5.4%. The respective coefficients of variation for other hemostatic indexes were as follows: FVIIc, 15.0% and 2.2%; FVIIa, 23.0% and 11.1%; FVIIag, 11.1% and 3.5%; F1+2, 25.0% and 7.6%; and FPA, 38.8% and 24.0%.
Tests were performed to determine whether the FXIIa assay was influenced by the quality of venepuncture,20 length of sample storage at -20°C to -80°C, or the time that the sample stood at room temperature before assay.
Follow-Up and End Points
The principal end points were first CHD events defined as any of
the following: (1) acute CHD, defined as sudden coronary death
or fatal and non-fatal MI (History, ECG, cardiac enzymes, and pathology
were assessed by an independent reviewer who classified events by WHO
criteria27 ); (2) silent MI, defined as new major Q waves
on the ECG (Minnesota codes 11,
12.1 through 12.7, and
12.8 plus 51 or
52)28 ; and (3) surgery for angina
pectoris with CHD angiographically demonstrated. Acute CHD alone was a
subsidiary end point.
Genotyping of the FXII C46T variant
DNA was extracted by the salting out method29 from
cells collected from blood taken into anticoagulant. With the use of
published sequence information,19 polymerase chain
reaction amplification of exon 1 of the FXII gene was performed using
the following primer pair to produce a fragment of 142 bp. The forward
primer was 5'-GAT AGG CAG CTG GAC CAA CG-3'; the reverse primer was
5'-TGA TAG CGA CCC CCC AGA AC-3'.
The sequence surrounding the C46T polymorphism contains a naturally occurring BsaHI restriction enzyme site. The C46 wild-type sequence (GACGCC) contains this BsaHI site, which is abolished in the T46 rare variant (GATGCC). In the presence of the C allele BsaHI digestion yields fragments of 116 and 26 bp, whereas in the presence of the T allele, digestion does not occur. Digested polymerase chain reaction fragments were separated as described elsewhere.30
Statistical Analysis
Univariate analysis of continuous
variables was by 1-way ANOVA. Variables were log transformed
when needed to normalize distributions and stabilize variance. Plasma
FXIIa levels were highly skewed; therefore, a Kruskal-Wallis
nonparametric test was used in preference to 1-way ANOVA.
Survival analysis used Cox’s proportional-hazards model, with
the significance of the parameters in the model assessed by
log likelihood ratio test. All results were exponentiated as hazard
ratios (95% CIs).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Of 2951 European respondents qualifying for follow-up, 2624 were genotyped. At the first annual reexamination, 2471 genotyped respondents were seen and known to be free of a CHD event. Stored plasma for determination of FXIIa at this reexamination was available for 1745 men who were followed up beyond this point.
Plasma FXIIa concentration was not different in the 23 men with an FPA of 10 nmol/L and those with lower FPA levels (P=0.16). However, although FXIIa concentrations were similar in those with satisfactory and less than satisfactory venepunctures, they appeared raised in 27 men with unsatisfactory venepunctures; the mean levels were 1.65, 1.49, and 2.07 ng/mL, respectively (P=0.004). Exclusion of these 27 had no effect on the results of the statistical analysis; therefore, the findings presented are for all 1745 respondents. The assay result was not affected by storage up to 12 months or by holding samples at room temperature for up to 6 hours.
Clotting Factors and Genotype
The distribution of genotypes for FXII was in
Hardy-Weinberg equilibrium, with frequencies as follows: CC, 56.7%;
CT, 36.9%; and TT, 6.6%. The relative frequency of the T allele
was 25% (95% CI, 24 to 27). Table 1
presents the mean or median
of characteristics significantly related to genotype. Median
FXIIa in the TT genotype was 40% of that in the CC group, with
that in the CT genotype intermediate (P<0.0001),
suggesting codominance. Similarly, mean FPA in the TT genotype
was 24% lower than that for the CC group, with men of CT
genotype intermediate (P<0.0001). Mean FVIIc was
lower by 
5% of standard in the TT genotype compared with
others (P=0.02), the difference remaining essentially
unchanged (P=0.045) after allowance for body mass index
(BMI) and triglyceride concentration. ‘Data were available
for FVIIc, FVIIag, and FVIIa at baseline, with associations with FXII
genotype being similar to that for FVIIc at 1 year of
follow-up: mean FVIIc (% standard): CC, 108; CT, 107; and TT, 101
(P=0.055); mean FVIIag (% standard): CC, 127; CT, 128; and
TT, 123 (P=0.087); mean FVIIa (ng/mL): CC, 2.05; CT, 1.80;
and TT, 1.50 (P=0.067).
|
Mean diastolic blood pressure (BP) was similar in the CC and CT genotypes but was 2.5 mm Hg lower in the TT group (P=0.03). Smoking status, systolic BP, BMI, cholesterol, triglycerides, fibrinogen, and F1+2 were unrelated to FXII genotype.
FXII and Conventional Risk Factors for CHD
Table 2 presents the
distributions of age, BMI, BP, cholesterol,
triglycerides, FVIIc, FXIIa, fibrinogen,
F1+2, and FPA in the 2471 subjects
genotyped and free of CHD at 1 year. When these distributions
were divided into thirds, clear trends to increasing FXIIa
concentration were observed with increasing values of all variables
(P<0.001 for linear trend) except
F1+2 and fibrinogen concentrations. The
associations of FXIIa with FVIIc and FPA were independent of
cholesterol and triglyceride concentrations
(r=0.08, P=0.002 and r=0.19,
P<0.0001 after adjustment, respectively). Furthermore, the
associations of FXIIa with BMI, BP, cholesterol,
triglycerides, FVIIc, and FPA were independent of its
association with risk of CHD (P<0.001 after adjustment
except for systolic BP, P=0.005).
|
FXII and CHD
Among the 2590 men genotyped and followed up, 139 (5.4%)
had a CHD event during 16 163 person-years of surveillance, and
97(3.8%) had acute CHD. In the CC group, 74 (5.1%) of 1462 men had a
CHD event compared with 60 (6.3%) of 969 in the CT group and 5 (3.0%)
of 169 with the TT genotype. In a Cox proportional-hazards
model with TT as the reference group, the hazard ratio did not differ
significantly between groups (P=0.12). These findings were
essentially unchanged when the analysis was repeated on acute
CHD alone.
In the 1745 men who were genotyped, had FXIIa determined, and
were followed up, 92 (5.3%) had a CHD event and 56 (3.2%) had acute
CHD. Median (interquartile range) FXIIa was 2.0 ng/mL (1.4 to 2.4
ng/mL) in the group of 92 compared with 1.7 ng/mL (1.2 to 2.2 ng/mL) in
those remaining free of the disorder (P=0.005,
Kruskal-Wallis test). Incidence rates of CHD per 1000 person-years by
thirds of the distribution of FXIIa were as follows: low (<1.5 ng/mL),
7.2; middle, 7.2; and high (>2.0 ng/mL), 13.6. The respective hazard
ratios with the low third as reference group were 1.01 (95% CI, 0.58
to 1.77) and 1.96 (95% CI, 1.20 to 3.20) (P=0.007,
likelihood ratio test). Thus, there was strong evidence for an
increased risk of CHD when FXIIa was >2.0 ng/mL. Table 3 shows that the estimate of hazard in
the high third remained significantly increased after adjustment for
genotype in a multivariate Cox model, whereas
genotype was unrelated to risk when FXIIa was taken into
account. After allowance for genotype, cholesterol,
triglycerides, fibrinogen, FVIIc, FPA, systolic BP,
and BMI, the adjusted hazard ratios in the middle and high thirds of
FXIIa (relative to low third) were 1.03 (95% CI, 0.56 to 1.90) and
2.05 (95% CI, 1.11 to 3.75; P=0.02), respectively. For
acute CHD alone, the respective estimates were 1.06 (95% CI, 0.51 to
2.19) and 2.14 (95% CI, 1.13 to 4.04; P=0.03).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The assay of apparent FXIIa appeared to be affected by an unsatisfactory venepuncture, but inclusion of these results did not alter the findings of the statistical analysis. With respect to sample handling, storage up to 12 months and standing at room temperature for up to 6 hours did not affect FXIIa concentration. Thus, although samples were collected with venepunctures of differing quality (93% were coded satisfactory) and stored frozen for varying periods, collection and handling procedures appeared not to have introduced errors that could lead to misinterpretation of the findings.
As reported by others,19 31 the CC genotype was associated with a significantly higher FXIIa concentration than homozygosity for the rare allele of the FXII genotype (TT). The C-T change creates a novel AUG methionine start-of-translation codon upstream of the correct AUG site, shown in vitro to result in less efficient translation of the T-mRNA compared with the C-mRMA.19 Unimpaired translation in the CC genotype results in relatively high FXII and FXIIa levels.
Novel findings in this study were the significantly lower levels of FVIIc and FPA in the FXII TT genotype compared with the CT and CC groups. On average, FVIIa was 27% lower in the TT group than the CC group (P=0.055). Studies in vitro have shown activation of FVII by FXIIa,14 but whether the same occurs in vivo is uncertain. Although the higher FVIIc and FVIIa levels in the CC group, who had the higher FXIIa levels, could have occurred by chance, they may indicate that the genotypically determined status of FXII has consequences for FVII activity in vivo. This conclusion agrees with findings in patients with hereditary angioedema, in whom C1 inhibitor is very low and the contact system is activated. Plasma FVIIa concentrations in such patients are significantly higher than in healthy control subjects, suggesting modest yet biologically important activation of FVII when FXIIa activity is raised.32 Furthermore, activation of FVII has been observed in rhesus monkeys after implantation of a porous chamber containing immobilized human FXIIa.33
The strong association between FXIIa and FPA levels, according to FXII genotype, suggested that an increase in FXIIa has consequences for the cleavage of FPA from fibrinogen. Unexpectedly, this effect was not accompanied by any increase in F1+2. Although there are no data within the study to address this observation further, the paradox could be explained by a reduction in antithrombin, which would result in lengthening of the half-life of thrombin. Similar apparent discrepancies have been observed in other studies. For example, in patients who suffered an acute MI but did not receive heparin, fibrin monomer was increased on the second day after the event in those who died or had a new MI within 90 days, whereas F1+2 concentration was normal at this time point.34
The genotype for FXII determines FXII concentration and therefore will contribute to the FXIIa level by mass action. This study has also shown that serum cholesterol and triglyceride concentrations account for some additional variability in FXIIa. Thus, plasma FXIIa concentration appears to be determined partly by FXII genotype, partly by plasma lipid levels, and partly by nonlipid factors that explain its association with CHD. The independent association of FXIIa with CHD and its relations with several major CHD risk factors suggested that FXIIa concentration serves as a marker of the extent and severity of atherosclerosis. Coppola et al35 reported a marked increase in FXIIa in patients with MI who had received thrombolytic therapy. Kohler et al17 found FXIIa concentration to be strongly associated with the extent of coronary artery stenosis.
The origin of an increased FXIIa in men at high risk of CHD is uncertain. One possible mechanism might be that activation of vascular endothelium or other cells involved in the atherosclerotic process enhances FXII activation. This would help explain why a low FXIIa concentration is not protective against CHD; increased concentrations are primarily a consequence rather than a cause of underlying vascular disease, although high FXIIa levels may conceivably play a secondary role in the disease process.
Six percent of men were of the TT genotype. Compared with the CC and CT genotypes, TT carried a crude hazard ratio of 0.42, although with a wide 95% CI (0.13 to 1.35), and in a Cox proportional-hazards model, there was no significant difference in risk of CHD by genotype. Larger studies are needed to state with confidence whether the TT genotype confers protection against CHD because of its relatively infrequent association with a high FXIIa concentration. However, if as suggested a high FXIIa level is an effect rather than a cause of the underlying pathology in CHD, such an inherited form of protection would seem a remote possibility.
|
Acknowledgments |
|---|
This study was supported by the British Medical Research Council, National Institutes of Health (HL-33014, HL-54502), and Du Pont Pharma (Wilmington, Del). Dr Zito is supported by a grant from The Wellcome Trust. Drs Drummond and Humphries are supported by the British Heart Foundation (RG007). We thank The Surgery, Aston Clinton; Upper Gordon Road Surgery, Camberley; The Health Center, Carnoustie; Whittington Moor Surgery, Chesterfield; The Market Place Surgery, Halesworth; The Health Center, Harefield; Potterells Medical Center, North Mymms; Rosemary Medical Center, Parkstone, Poole; and The Health Center, St Andrews, for collaboration. Jacqueline Mitchell and David Howarth performed the FVII and FXII assays, and Samad Barzegar performed the F1+2 and FPA assays. Lily Li provided technical assistance with genotyping. Axis-Shield donated the FXIIa kits, and Novo Nordisk provided the kits for FVIIag.
|
Footnotes |
|---|
Dr Esnouf is a shareholder of Axis-Shield (Dundee, UK), suppliers of the ELISA for activated factor XII.
Received April 24, 2000; revision received June 5, 2000; accepted June 5, 2000.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Saito H. The contact phase of blood coagulation. In: Bloom AL, Forbes CD, Thomas DP, et al, eds. Haemostasis and Thrombosis. 3rd ed. London, UK: Churchill Livingstone; 1994:289–307.
2. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med. 1974;140:797–811.[Abstract]
3.
Hojima Y, Cochrane CG, Wiggins RC, et al. In vitro
activation of the contact (Hageman factor) system of plasma by heparin
and chondroitin sulfate. Blood. 1984;63:1453–1459.
4.
Reddigari SR, Shibayama T, Brunee T, et al. Human
Hageman factor (factor XII) and high molecular weight kininogen compete
for the same binding site on human umbilical vein
endothelial cells. J Biol Chem. 1993;268:11982–11987.
5.
van Iwaarden F, de Groot PG, Bouma BN. The binding of
high molecular weight kininogen to cultured human
endothelial cells. J Biol Chem. 1988;263:4698–4703.
6.
Bouma BN, Griffin JH. Human blood coagulation factor
XI: purification, properties, and mechanism of activation by
activated factor XII. J Biol Chem. 1977;252:6432–6437.
7.
Mandle R, Kaplan AP. Hageman factor substrates: human
plasma prekallikrein: mechanism of activation by
Hageman factor and participation in Hageman factor-dependent
fibrinolysis. J Biol Chem. 1977;252:6097–6104.
8.
Kerbiriou DM, Griffin JH. Human high molecular weight
kininogen: studies of structure-function relationships and of
proteolysis of the molecule occurring during contact activation of
plasma. J Biol Chem. 1979;254:12020–12027.
9. Osmond DH, Loh EK, Zingg EA, et al. Kallikrein and plasmin as activators of inactive renin. Lancet. 1978;2:1375–1376.[Medline] [Order article via Infotrieve]
10. Nagase H, Cawston JE, De Silva M, et al. Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta. 1982;702:133–142.[Medline] [Order article via Infotrieve]
11.
Jansen PM, Pixley RA, Brouwer M, et al. Inhibition of
factor XII in septic baboons attenuates the activation of complement
and fibrinolytic systems and reduces the release of interleukin 6 and
neutrophil elastase. Blood. 1996;87:2337–2344.
12. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, ß-factor XIIa, factor XIa, and urokinase to activate plasminogen. Thromb Res. 1983;29:407–417.[Medline] [Order article via Infotrieve]
13. Ratnoff OD, Davie EW. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI). Biochemistry. 1962;1:677–685.
14. Seligsohn U, Osterud G, Brown SF, et al. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest. 1979;64:1056–1065.
15. Gordon EM, Hellerstein HK, Ratnoff OD, et al. Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction. J Lab Clin Med. 1987;109:409–413.[Medline] [Order article via Infotrieve]
16. Kelleher CC, Mitropoulos KA, Imeson J, et al. Hageman factor and risk of myocardial infarction in middle-aged men. Atherosclerosis. 1992;92:67–73.[Medline] [Order article via Infotrieve]
17. Kohler HP, Carter AM, Stickland MH, et al. Levels of activated FXII in survivors of myocardial infarction: association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 1998;79:14–18.[Medline] [Order article via Infotrieve]
18.
Miller GJ, Esnouf MP, Burgess AI, et al. Risk of
coronary heart disease and activation of factor XII in
middle-aged men. Arterioscler Thromb Vasc Biol. 1997;17:2103–2106.
19. Kanaji T, Okamura T, Osaki K, et al. A common genetic polymorphism (46C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood. 1998;6:2010–2014.
20. Miller GJ, Bauer KA, Barzegar S, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost. 1995;73:82–86.[Medline] [Order article via Infotrieve]
21. Bauer KA, Barzegar S, Rosenberg RD. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1+2 measurements. Thromb Res. 1991;63:617–628.[Medline] [Order article via Infotrieve]
22. Miller GJ, Stirling Y, Esnouf MP, et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bioassay to activated factor VII: an international study. Thromb Haemost. 1994;71:38–48.[Medline] [Order article via Infotrieve]
23.
Morrissey JH, Macik BG, Neuenschwander PF, et al.
Quantitation of activated factor VII levels in plasma using a
tissue factor mutant selectively deficient in promoting factor VII
activation. Blood. 1993;81:734–744.
24. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237–246.[Medline] [Order article via Infotrieve]
25.
Teitel JM, Bauer KA, Lau HK, et al. Studies of the
prothrombin activation pathway utilizing radioimmunoassays for the
F2/F1+2 fragment and
thrombin-antithrombin complex. Blood. 1982;59:1086–1097.
26.
Esnouf MP, Burgess AI, Dodds AW, et al. A monoclonal
antibody raised against human ß-factor XIIa which also recognises
-factor XIIa but not factor XII or complexes of factor XIIa with C1
esterase inhibitor. Thromb Haemost. 2000;
83:874–882.
27. World Health Organization Regional Office for Europe. Myocardial Infarction Community Registers: Public Health in Europe, No. 5. Copenhagen, Amsterdam: WHO; 1976.
28. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement and Classification. Boston, Mass: John Wright, PSC Inc; 1982.
29.
Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated cells. Nucleic
Acids Res. 1988;16:1215.
30. Day INM, Humphries S. Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal Biochem. 1994;222:389–395.[Medline] [Order article via Infotrieve]
31.
Kohler HP, Futers TS, Grant PJ. FXII (46C
T)
polymorphism and in vivo generation of FXII activity. Thromb
Haemost. 1999;81:745–747.[Medline]
[Order article via Infotrieve]
32. Nielson EW, Morrissey J, Olsen JO, et al. Factor VIIa in patients with C1-inhibitor deficiency. Thromb Haemost. 1995;74:1103–1106.[Medline] [Order article via Infotrieve]
33. Ton-That TT, Doron D, Pollard BS, et al. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nature Biotech. 2000;18:289–295.[Medline] [Order article via Infotrieve]
34. Dempfle C-E, Kontny F, Abildgaard U. Predictive value of coagulation markers concerning clinical outcome 90 days after anterior myocardial infarction. Thromb Haemost. 1999;81:701–704.[Medline] [Order article via Infotrieve]
35. Coppola R, Cristilli P, Cugno M, et al. Measurement of activated factor XII in health and disease. Blood Coagul Fibrinolysis. 1996;7:530–535.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  M. Y. Chan, F. Andreotti, and R. C. Becker Hypercoagulable States in Cardiovascular Disease Circulation, November 25, 2008; 118(22): 2286 - 2297. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gailani and T. Renne Intrinsic Pathway of Coagulation and Arterial Thrombosis Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2507 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Sanders, F. Lewis, S. Slaughter, B. A Griffin, M. Griffin, I. Davies, D J. Millward, J. A Cooper, and G. J Miller Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of {alpha}-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45-70 y: the OPTILIP Study. Am. J. Clinical Nutrition, September 1, 2006; 84(3): 513 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Renne, M. Pozgajova, S. Gruner, K. Schuh, H.-U. Pauer, P. Burfeind, D. Gailani, and B. Nieswandt Defective thrombus formation in mice lacking coagulation factor XII J. Exp. Med., July 18, 2005; 202(2): 271 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Santamaria, J. Mateo, I. Tirado, A. Oliver, R. Belvis, J. Marti-Fabregas, R. Felices, J. M. Soria, J. C. Souto, and J. Fontcuberta Homozygosity of the T Allele of the 46 C->T Polymorphism in the F12 Gene Is a Risk Factor for Ischemic Stroke in the Spanish Population Stroke, August 1, 2004; 35(8): 1795 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Humphries, P. M. Ridker, and P. J. Talmud Genetic Testing for Cardiovascular Disease Susceptibility: A Useful Clinical Management Tool or Possible Misinformation? Arterioscler Thromb Vasc Biol, April 1, 2004; 24(4): 628 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Papageorgiou, A. Pourdjabbar, A. A. Amfilochiadis, E. P. Diamandis, F. Boomsma, and D. H. Osmond Are cardiovascular and sympathoadrenal effects of human "new pressor protein" preparations attributable to human coagulation {beta}-FXIIa? Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H837 - H846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zitzmann, R. Junker, A. Kamischke, and E. Nieschlag Contraceptive Steroids Influence the Hemostatic Activation State in Healthy Men J Androl, July 1, 2002; 23(4): 503 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Klein, M. Spannagl, and B. Engelmann Phosphatidylethanolamine Participates in the Stimulation of the Contact System of Coagulation by Very-Low-Density Lipoproteins Arterioscler Thromb Vasc Biol, October 1, 2001; 21(10): 1695 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Orth, S. Westphal, J. Dierkes, C. Luley, and K. Schlatterer Rapid Factor XII (46C{->}T) Genotyping by Fluorescence Resonance Energy Transfer in Patients with Coronary Artery Disease or Thrombophilia Clin. Chem., June 1, 2001; 47(6): 1117 - 1119. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||